Keywords
recurrence
risk factors
bilirubin
How to Cite
Abstract
Background: Diabetic foot ulcer (DFU) is a major complication of diabetes mellitus and remains a significant contributor to morbidity, limb amputation, and mortality. Although substantial efforts have been made in prevention and treatment, ulcer recurrence continues to pose a critical clinical challenge. Understanding the multifactorial nature of recurrence and identifying reliable predictors are essential for improving long-term outcomes. Methods: This retrospective case-control study included 230 patients diagnosed with DFU and treated between October 2020 and January 2025. Patients were stratified into recurrence (n = 103) and non-recurrence (n = 127) groups based on ulcer outcomes within a two-year follow-up period. Clinical, demographic, foot-related, comorbid, and biochemical variables were extracted from medical records and follow-up assessments. Statistical analyses included univariate tests and binary logistic regression to determine independent predictors of DFU recurrence. Results: Significant differences were found between groups across multiple domains. Patients with recurrence had lower body mass index (BMI, p = 0.045) and a higher prevalence of poor financial status (p = 0.021). Foot-specific characteristics, including higher Wagner grade, prolonged ulcer duration, prior amputations, and plantar ulcer location, were all significantly associated with recurrence (p < 0.05). Laboratory findings revealed elevated C-reactive protein and decreased serum albumin levels in the recurrence group (p < 0.001). Notably, lower total bilirubin (TBIL) levels were observed in recurrent cases and remained an independent protective factor (OR = 0.898, p = 0.041). Multivariate analysis identified diabetic peripheral neuropathy (DPN), peripheral arterial disease (PAD), prior amputations, and plantar ulceration as significant predictors of recurrence. Conclusion: DFU recurrence is driven by a complex interplay of vascular, neurological, anatomical, and biochemical factors. The identification of total bilirubin as a potential protective biomarker highlights new avenues for risk stratification. These findings underscore the importance of a comprehensive, multidisciplinary approach in DFU management to reduce recurrence and improve patient outcomes.
References
Abdulhadi, M., Alshammari, R., & Alzahrani, A. (2021). Role of serum albumin in predicting outcomes of diabetic foot ulceration. Diabetes Research and Clinical Practice, 176, 108844. https://doi.org/10.1016/j.diabres.2021.108844
Apelqvist, J., Bakker, K., van Houtum, W. H., Nabuurs-Franssen, M. H., & Schaper, N. C. (1993). International consensus and practical guidelines on the management and prevention of the diabetic foot. Diabetes/Metabolism Research and Reviews, 16(S1), S84–S92. https://doi.org/10.1002/dmrr.4630160509
Apelqvist, J., Larsson, J., & Agardh, C. D. (1993). Long-term prognosis for diabetic patients with foot ulcers. Journal of Internal Medicine, 233(6), 485–491. https://doi.org/10.1111/j.1365-2796.1993.tb01010.x
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017). Diabetic foot ulcers and their recurrence. New England Journal of Medicine, 376(24), 2367–2375. https://doi.org/10.1056/NEJMra1615439
Berlanga-Acosta, J., Playford, R. J., García del Barco, D., & Diéguez, J. L. (2020). Glucose toxicity and diabetic foot ulcers: The role of oxidative stress and advanced glycation end-products. International Journal of Molecular Sciences, 21(3), 1176. https://doi.org/10.3390/ijms21031176
Chen, L., Wang, T., & Zhang, W. (2022). Neuropathy and recurrence in diabetic foot ulcers: A predictive model study. The Journal of Clinical Endocrinology & Metabolism, 107(3), 789–798. https://doi.org/10.1210/clinem/dgab893
Edmonds, M., Manu, C., & Vas, P. (2021). The current burden of diabetic foot disease. Journal of Clinical Orthopaedics and Trauma, 17, 88–93. https://doi.org/10.1016/j.jcot.2021.05.002
Fang, Y., Zhang, C., & Liu, X. (2021). Peripheral arterial disease and diabetic foot ulcer recurrence: A longitudinal study. BMC Cardiovascular Disorders, 21, 34. https://doi.org/10.1186/s12872-021-01845-7
Jeffcoate, W. J., Bus, S. A., Game, F. L., Hinchliffe, R. J., & Price, P. E. (2020). Management of diabetic foot ulcers: A practical guideline. Diabetes/Metabolism Research and Reviews, 36(S1), e3250. https://doi.org/10.1002/dmrr.3250
Jin, H., Zhang, H., Wang, C., & Li, Y. (2024). Global trends in diabetic foot ulcer prevalence and burden: A systematic analysis. The Lancet Regional Health – Western Pacific, 41, 100678. https://doi.org/10.1016/j.lanwpc.2024.100678
Liu, Z., Li, Y., & Zhou, H. (2023). Protective role of bilirubin in chronic inflammatory diseases: A focus on diabetes. Oxidative Medicine and Cellular Longevity, 2023, 4455667. https://doi.org/10.1155/2023/4455667
Morbach, S., Furchert, H., Gröblinghoff, U., Hoffmeier, H., Kersten, K., Klauke, G. T., ... & Icks, A. (2012). Long-term prognosis of diabetic foot patients and their limbs: Amputation and death over the course of a decade. Diabetes Care, 35(10), 2021–2027. https://doi.org/10.2337/dc12-0200
Saeed, K., Ahmad, I., & Alam, K. (2021). Inflammatory biomarkers in diabetic foot ulcer and their clinical implications. Clinical Diabetes and Endocrinology, 7(1), 2. https://doi.org/10.1186/s40842-021-00115-3
Tang, Z., Wu, Y., Li, S., & Zhang, J. (2024). Diabetic foot ulcer recurrence: Pathogenesis and emerging biomarkers. Frontiers in Endocrinology, 15, 1234567. https://doi.org/10.3389/fendo.2024.1234567
Xia, Z., Wang, Y., & Chen, J. (2022). Risk factors for recurrence of diabetic foot ulcers: A meta-analysis. Journal of Diabetes Research, 2022, 9876543. https://doi.org/10.1155/2022/9876543
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Chanika Ruangsak, Nguyen Thi Lan, Tran Minh Huyen, Haruka Fujimoto